F3 and cancer: NC-6300 has also been conjugated with an antitissue factor mAb (clone 1849) for targeted cancer therapy, since tissue factor (TF), an initiator of the extrinsic blood coagulation cascade, is frequently overexpressed in cancer cells and tumor vascular endothelium [162].